Medicare AdvantagePrior AuthMedium impact
Sotyktu (deucravacitinib) (Revised)
Humana·Dermatology, Rheumatology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated prior authorization requirements for Sotyktu (deucravacitinib) for treating plaque psoriasis and psoriatic arthritis. The policy requires members to have tried or been unable to use two specific preferred medications before approving Sotyktu, with approval durations set to plan year periods.
Action Required
By January 1, 2026: Billing team must update prior authorization procedures for Sotyktu (deucravacitinib) prescriptions for Humana Medicare Advantage patients. Ensure documentation shows patients have tried or cannot use two of the specified preferred medications (Humira, Enbrel, Cosentyx, Skyrizi, Stelara/Otulfi/Yesintek, Tremfya, or Rinvoq for psoriatic arthritis). Update EMR templates to capture required criteria including diagnosis confirmation, age verification (18+), and prior therapy documentation. Claims will require prior authorization approval.